APA (7th ed.) Citation

Pfaff, E., Adam de Beaumais, T., Marchais, A., Tilburg, C. M. v., Blattner-Johnson, M., Dirksen, U., . . . Vassal, G. (2021). NTRK alterations in pediatric high-risk malignancies identified through European clinical sequencing programs constitute promising drug targets. JCO precision oncology, 5, . https://doi.org/10.1200/PO.20.00417

Chicago Style (17th ed.) Citation

Pfaff, Elke, et al. "NTRK Alterations in Pediatric High-risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets." JCO Precision Oncology 5 (2021). https://doi.org/10.1200/PO.20.00417.

MLA (9th ed.) Citation

Pfaff, Elke, et al. "NTRK Alterations in Pediatric High-risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets." JCO Precision Oncology, vol. 5, 2021, https://doi.org/10.1200/PO.20.00417.